101 related articles for article (PubMed ID: 15081868)
1. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.
Efferth T; Ramirez T; Gebhart E; Halatsch ME
Biochem Pharmacol; 2004 May; 67(9):1689-700. PubMed ID: 15081868
[TBL] [Abstract][Full Text] [Related]
2. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.
Halatsch ME; Gehrke EE; Vougioukas VI; Bötefür IC; A-Borhani F; Efferth T; Gebhart E; Domhof S; Schmidt U; Buchfelder M
J Neurosurg; 2004 Mar; 100(3):523-33. PubMed ID: 15035290
[TBL] [Abstract][Full Text] [Related]
3. Molecular modes of action of artesunate in tumor cell lines.
Efferth T; Sauerbrey A; Olbrich A; Gebhart E; Rauch P; Weber HO; Hengstler JG; Halatsch ME; Volm M; Tew KD; Ross DD; Funk JO
Mol Pharmacol; 2003 Aug; 64(2):382-94. PubMed ID: 12869643
[TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
6. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
7. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
10. Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines.
Learn PA; Krishnegowda N; Talamantez J; Kahlenberg MS
J Surg Res; 2006 Dec; 136(2):227-31. PubMed ID: 17059835
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
[TBL] [Abstract][Full Text] [Related]
12. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Efferth T; Sauerbrey A; Halatsch ME; Ross DD; Gebhart E
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):56-67. PubMed ID: 12616342
[TBL] [Abstract][Full Text] [Related]
13. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Zhao Q; Kretschmer N; Bauer R; Efferth T
Int J Cancer; 2015 Sep; 137(6):1446-56. PubMed ID: 25688715
[TBL] [Abstract][Full Text] [Related]
14. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
Cunningham MP; Thomas H; Fan Z; Modjtahedi H
Cancer Res; 2006 Aug; 66(15):7708-15. PubMed ID: 16885373
[TBL] [Abstract][Full Text] [Related]
15. Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib.
Löw S; Vougioukas VI; Hielscher T; Schmidt U; Unterberg A; Halatsch ME
Anticancer Res; 2008; 28(6A):3729-32. PubMed ID: 19189657
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K
Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420
[TBL] [Abstract][Full Text] [Related]
17. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
18. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
Matheson SL; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
Chakravarti A; Loeffler JS; Dyson NJ
Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]